REGULATORY
Generic Approval Roster Includes at Least 3 AGs; Azilva, Revlimid, Maintate
At least three authorized generics (AGs) were among a throng of generics approved on February 15 towards generic listing in June. This includes AGs for the hypertension drug Azilva (azilsartan) and the blood cancer med Revlimid (lenalidomide). Azilva, an angiotensin…
To read the full story
Related Article
REGULATORY
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
- MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
- MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
- Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





